VanEck Pharmaceutical ETF PPH
120.19 USD -1.90 (-1.56%)
Nov 5, 2026, 12:34 PM EST
120.09 Day range 123.50
93.11 52-week range 123.50
- YTD
- +16.50%
- 1 year
- +28.30%
- Market cap
- 1.16B
- EPS (ttm)
- 4.29
- P/E ratio
- 28.04
- YTD return
- +16.50%
- 1-year return
- +28.30%
- Volume
- 168.15K
- Avg volume
- 315.99K
- Open
- 122.74
- Previous close
- 122.09
- Day's range
- 120.09 – 123.50
- 52-week range
- 93.11 – 123.50
2Y +30.11 (+33.18%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 112.68
- 200-day average
- 108.05
About VanEck Pharmaceutical ETF
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
News
Can GLP-1s Fatten Your Portfolio? We Examine the VanEck Pharmaceutical ETF vs State Street SPDR Pharmaceuticals ETF 
PPH: Key Pharmaceutical Innovations Support Bullish Outlook (Upgrade) 
Which Pharmaceutical ETF Is the Better Buy: iShares’ Domestic IHE or VanEck’s Global PPH? 
Which Healthcare ETF Is the Better Buy: Simplify's Active PINK or VanEck's Pharma-Focused PPH? 
Execution of Pharma Tariffs Brings These ETFs Into Focus 
Should You Invest in the VanEck Pharmaceutical ETF (PPH)? 
Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP 
VanEck Pharmaceutical ETF vs VanEck Biotech ETF: Which Fund Is Better for Drug Innovation Profits? 
Should You Bet Big on Drugmakers? VanEck Pharmaceutical ETF vs. 
Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough
Your note
Sign in to keep a note on PPH — it syncs with the Stock Master app.